UNSPSC 51284024: Doxycycline anhydrous

This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 334895S862, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.alpha.,12a.alpha.))-, but more generally known as doxycycline anhydrous, which bears US NIH Compound Identifier 5281011.

UNSPSC 51284024 Doxycycline anhydrous is a Commodity code that describes a specific antibiotic pharmaceutical product, but the recent state and local opportunities tagged under it show minimal direct purchasing activity for doxycycline itself and instead reflect broader pharmaceutical procurement — notably generic multi-source drugs, naloxone, and medical supply procurement through cooperative and individual jurisdictional channels. State and local government bodies soliciting under this code include county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances spanning multiple states. The scope of work under the code encompasses acquisition of pharmaceutical products for emergency response, public health initiatives, and routine medical supply distribution to government facilities and personnel.

Activity is geographically dispersed across Florida, Texas, and Minnesota, with representation in multistate cooperative purchasing vehicles. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to the county health building; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for medical and first aid supplies supporting the fire department rescue division, designated as a sheltered market for certified Small Local Business Enterprises with an estimated contract value of $700,000; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic pharmaceuticals and OTC products distributed across state and local facilities. The MMCAP RFP reflects the pattern of pharmaceutical procurement through cooperative vehicles with authorized wholesalers and establishes an effective contract date of July 1, 2026.